Literature DB >> 3485111

Subunit composition of plasma von Willebrand factor. Cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease, but minimal in variants with aberrant structure of individual oligomers (types IIC, IID, and IIE).

T S Zimmerman, J A Dent, Z M Ruggeri, L H Nannini.   

Abstract

We have evaluated the subunit composition of plasma von Willebrand factor (vWF) and found evidence that cleavage is present in normal individuals, increased in IIA and IIB von Willebrand disease (vWD), but decreased or absent in variants with aberrant structure of individual oligomers. vWF was rapidly purified from plasma on an analytical scale by monoclonal antibody immunoaffinity chromatography in the presence of protease inhibitors. After reduction and electrophoresis in 5% polyacrylamide gels containing sodium dodecyl sulfate, fragments of 189, 176, and 140 kD, as well as the predominant 225-kD subunit, were identified in plasma vWF from 25 normal individuals. The vWF polypeptides were detected by immunoblotting with a mixture of 55 anti-vWF monoclonal antibodies followed by 125I-rabbit anti-mouse antibody and autoradiography. In five individuals with type IIA and five individuals with type IIB vWD, the proportions of 176 and 140-kD fragments were increased relative to the intact 225-kD subunit, as determined by excising each band and quantitating incorporated radioactivity. In contrast, these fragments were either not detectable or were present in only trace amounts in variants with abnormal structure of individual oligomers (types IIC and IID, and a new variant, type IIE vWD). The results reported here provide evidence that absence of large vWF multimers in these two groups of variants results from different mechanisms. In addition, they demonstrate that partial cleavage of the plasma vWF subunit is a normal event.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485111      PMCID: PMC423489          DOI: 10.1172/JCI112394

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  18 in total

1.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

2.  A variant of von Willebrand's disease characterized by recessive inheritance and missing triplet structure of von Willebrand factor multimers.

Authors:  P M Mannucci; R Lombardi; F I Pareti; S Solinas; M G Mazzucconi; G Mariani
Journal:  Blood       Date:  1983-11       Impact factor: 22.113

3.  Variant von Willebrand's disease: characterization of two subtypes by analysis of multimeric composition of factor VIII/von Willebrand factor in plasma and platelets.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  J Clin Invest       Date:  1980-06       Impact factor: 14.808

4.  Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody.

Authors:  C A Fulcher; T S Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1982-03       Impact factor: 11.205

5.  Heightened interaction between platelets and factor VIII/von Willebrand factor in a new subtype of von Willebrand's disease.

Authors:  Z M Ruggeri; F I Pareti; P M Mannucci; N Ciavarella; T S Zimmerman
Journal:  N Engl J Med       Date:  1980-05-08       Impact factor: 91.245

6.  Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in Type IIB von Willebrand's disease.

Authors:  L Holmberg; I M Nilsson; L Borge; M Gunnarsson; E Sjörin
Journal:  N Engl J Med       Date:  1983-10-06       Impact factor: 91.245

7.  Aberrant multimeric structure of von Willebrand factor in a new variant of von Willebrand's disease (type IIC).

Authors:  Z M Ruggeri; I M Nilsson; R Lombardi; L Holmberg; T S Zimmerman
Journal:  J Clin Invest       Date:  1982-11       Impact factor: 14.808

8.  Properties of human asialo-factor VIII. A ristocetin-independent platelet-aggregating agent.

Authors:  L De Marco; S S Shapiro
Journal:  J Clin Invest       Date:  1981-08       Impact factor: 14.808

9.  von Willebrand disease type IIC with different abnormalities of von Willebrand factor in the same sibship.

Authors:  J Batlle; M F Lopez Fernandez; J Lasierra; A Fernandez Villamor; C Lopez Berges; A Lopez Borrasca; Z M Ruggeri; T S Zimmerman
Journal:  Am J Hematol       Date:  1986-02       Impact factor: 10.047

10.  The complex multimeric composition of factor VIII/von Willebrand factor.

Authors:  Z M Ruggeri; T S Zimmerman
Journal:  Blood       Date:  1981-06       Impact factor: 22.113

View more
  38 in total

Review 1.  Current understanding of the pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  S L Allford; S J Machin
Journal:  J Clin Pathol       Date:  2000-07       Impact factor: 3.411

2.  von Willebrand factor and factor VIII are independently required to form stable occlusive thrombi in injured veins.

Authors:  Anil K Chauhan; Janka Kisucka; Colin B Lamb; Wolfgang Bergmeier; Denisa D Wagner
Journal:  Blood       Date:  2006-11-21       Impact factor: 22.113

3.  Size regulation of von Willebrand factor-mediated platelet thrombi by ADAMTS13 in flowing blood.

Authors:  Roberta Donadelli; Jennifer N Orje; Cristina Capoferri; Giuseppe Remuzzi; Zaverio M Ruggeri
Journal:  Blood       Date:  2005-11-17       Impact factor: 22.113

4.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

5.  Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized.

Authors: 
Journal:  P T       Date:  2010-01

6.  Pathological von Willebrand factor fibers resist tissue plasminogen activator and ADAMTS13 while promoting the contact pathway and shear-induced platelet activation.

Authors:  B A Herbig; S L Diamond
Journal:  J Thromb Haemost       Date:  2015-07-28       Impact factor: 5.824

Review 7.  Diagnostic approach to von Willebrand disease.

Authors:  Christopher Ng; David G Motto; Jorge Di Paola
Journal:  Blood       Date:  2015-02-23       Impact factor: 22.113

8.  LIM kinase/cofilin dysregulation promotes macrothrombocytopenia in severe von Willebrand disease-type 2B.

Authors:  Alexandre Kauskot; Sonia Poirault-Chassac; Frédéric Adam; Vincent Muczynski; Gabriel Aymé; Caterina Casari; Jean-Claude Bordet; Christelle Soukaseum; Chantal Rothschild; Valérie Proulle; Audrey Pietrzyk-Nivau; Eliane Berrou; Olivier D Christophe; Jean-Philippe Rosa; Peter J Lenting; Marijke Bryckaert; Cécile V Denis; Dominique Baruch
Journal:  JCI Insight       Date:  2016-10-06

9.  Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13.

Authors:  Kenji Nishio; Patricia J Anderson; X Long Zheng; J Evan Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

10.  Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications.

Authors:  Almudena Pérez-Rodríguez; Aranzazu García-Rivero; Esther Lourés; Maria Fernanda López-Fernández; Angela Rodríguez-Trillo; Javier Batlle
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.